Wave Life Sciences (WVE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.13, -1.88% vs the prior close of $3.19.
- Volume 3.28M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
WVE dips 1.9% to $3.13. Closed at $3.13, -1.88% vs the prior close of $3.19. Day range $3.08–$3.28, opened at $3.24.
WVE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — WVE dips 1.9% to $3.13
- Closed at $3.13, -1.88% vs the prior close of $3.19. Day range $3.08–$3.28, opened at $3.24.
- Volume was 3.28M shares, 1.0x its 50-day average of 3.40M.
- Price is -29.9% vs its 50-day average ($4.47) and -60.9% vs its 200-day average ($8.00).
- 52-week range $3.04–$21.73; today's close sits at 0% of that range, 85.6% below the 52-week high.
Oct 15, 2026 — WVE jumps 3.2% to $3.19
- Closed at $3.19, +3.24% vs the prior close of $3.09. Day range $3.08–$3.23, opened at $3.13.
- Volume was 3.35M shares, 1.0x its 50-day average of 3.37M.
- Price is -29.5% vs its 50-day average ($4.53) and -60.5% vs its 200-day average ($8.07).
- 52-week range $3.04–$21.73; today's close sits at 1% of that range, 85.3% below the 52-week high.
Oct 14, 2026 — WVE dips 1.6% to $3.09, a 52-week low, 5 down days in a row
- Closed at $3.09, -1.59% vs the prior close of $3.14. Day range $3.04–$3.13, opened at $3.09.
- Volume was 2.82M shares, 0.8x its 50-day average of 3.36M.
- Price is -32.5% vs its 50-day average ($4.58) and -62.1% vs its 200-day average ($8.15).
- 52-week range $3.04–$21.73; today's close sits at 0% of that range, 85.8% below the 52-week high.
- That makes 5 straight losses.
- SEC filings that day: DEF 14A.
Oct 13, 2026 — WVE slides 4.3% to $3.14, a 52-week low, 4 down days in a row
- Closed at $3.14, -4.27% vs the prior close of $3.28. Day range $3.07–$3.27, opened at $3.27.
- Volume was 4.18M shares, 1.3x its 50-day average of 3.35M.
- Price is -32.3% vs its 50-day average ($4.64) and -61.8% vs its 200-day average ($8.22).
- 52-week range $3.07–$21.73; today's close sits at 0% of that range, 85.5% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — WVE slides 5.2% to $3.28, a 52-week low, 3 down days in a row
- Closed at $3.28, -5.20% vs the prior close of $3.46. Day range $3.27–$3.46, opened at $3.46.
- Volume was 2.26M shares, 0.7x its 50-day average of 3.36M.
- Price is -30.1% vs its 50-day average ($4.69) and -60.5% vs its 200-day average ($8.30).
- 52-week range $3.27–$21.73; today's close sits at 0% of that range, 84.9% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — WVE ends flat (-0.3%) to $3.46, a 52-week low
- Closed at $3.46, -0.29% vs the prior close of $3.47. Day range $3.43–$3.53, opened at $3.49.
- Volume was 1.66M shares, 0.5x its 50-day average of 3.39M — lighter than usual.
- Price is -26.9% vs its 50-day average ($4.74) and -58.6% vs its 200-day average ($8.37).
- 52-week range $3.37–$21.73; today's close sits at 0% of that range, 84.1% below the 52-week high.
Oct 8, 2026 — WVE dips 2.0% to $3.47, a 52-week low
- Closed at $3.47, -1.98% vs the prior close of $3.54. Day range $3.37–$3.51, opened at $3.48.
- Volume was 2.66M shares, 0.8x its 50-day average of 3.38M.
- Price is -27.4% vs its 50-day average ($4.78) and -58.9% vs its 200-day average ($8.44).
- 52-week range $3.37–$21.73; today's close sits at 1% of that range, 84.0% below the 52-week high.
Oct 7, 2026 — WVE rises 0.6% to $3.54
- Closed at $3.54, +0.57% vs the prior close of $3.52. Day range $3.43–$3.60, opened at $3.48.
- Volume was 3.05M shares, 0.9x its 50-day average of 3.37M.
- Price is -26.7% vs its 50-day average ($4.83) and -58.4% vs its 200-day average ($8.50).
- 52-week range $3.43–$21.73; today's close sits at 1% of that range, 83.7% below the 52-week high.
Oct 6, 2026 — WVE slides 6.1% to $3.52, a 52-week low, 3 down days in a row
- Closed at $3.52, -6.13% vs the prior close of $3.75. Day range $3.48–$3.82, opened at $3.78.
- Volume was 3.45M shares, 1.0x its 50-day average of 3.34M.
- Price is -27.8% vs its 50-day average ($4.87) and -58.9% vs its 200-day average ($8.56).
- 52-week range $3.48–$21.73; today's close sits at 0% of that range, 83.8% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — WVE dips 0.8% to $3.75
- Closed at $3.75, -0.79% vs the prior close of $3.78. Day range $3.71–$3.88, opened at $3.81.
- Volume was 3.51M shares, 1.1x its 50-day average of 3.31M.
- Price is -23.8% vs its 50-day average ($4.92) and -56.5% vs its 200-day average ($8.63).
- 52-week range $3.56–$21.73; today's close sits at 1% of that range, 82.7% below the 52-week high.
Oct 2, 2026 — WVE dips 2.6% to $3.78
- Closed at $3.78, -2.58% vs the prior close of $3.88. Day range $3.77–$3.96, opened at $3.89.
- Volume was 3.74M shares, 1.1x its 50-day average of 3.28M.
- Price is -23.9% vs its 50-day average ($4.96) and -56.5% vs its 200-day average ($8.69).
- 52-week range $3.56–$21.73; today's close sits at 1% of that range, 82.6% below the 52-week high.
WVE latest news & SEC filings
Every SEC filing by or about WVE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Oct 14, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ra Capital Management, L.P. & Ra Capital Healthcare Fund Lp & Kolchinsky Peter & Shah Rajeev M. received an award of 10,700 shares on Oct 5, 2026; now holds 39,515
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Verdine Gregory L. received an award of 10,700 shares on Oct 5, 2026; now holds 200,917
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tan Aik Na received an award of 10,700 shares on Oct 5, 2026; now holds 35,668
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Takanashi Ken received an award of 10,700 shares on Oct 5, 2026; now holds 30,779
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Corrigan Mark received an award of 10,700 shares on Oct 5, 2026; now holds 39,515
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Rawcliffe Adrian received an award of 10,700 shares on Oct 5, 2026; now holds 10,700
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 11, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 15-12G — Notice to deregister securities
Notice to deregister securities
Aug 10, 2026 · Form POS AM — POS AM filing
POS AM filing
Aug 10, 2026 · Form POSASR — POSASR filing
POSASR filing
Aug 10, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Aug 10, 2026 · Form S-8 POS — S-8 POS filing
S-8 POS filing
Things to know before you trade WVE
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Apr 28, 2026, Feb 26, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.85% (largest 9.2%).
- Liquidity: about 3.30M shares (≈$10.34M) trade per day on average.
- 52-week position: $3.13 vs a range of $3.04–$21.73 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 9 open-market buys, 16 sales; latest: Adrian Rawcliffe sold 12,700 shares on Aug 12, 2026.
- Latest filings: 10-Q Jul 30, 2026; 8-K Jul 30, 2026; 8-K Jun 26, 2026.
- Share count: 197.05M shares outstanding (Jul 23, 2026), +23.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
WVE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.24 | 3.28 | 3.08 | 3.13 | 3.28M |
| Oct 15, 2026 | 3.13 | 3.23 | 3.08 | 3.19 | 3.35M |
| Oct 14, 2026 | 3.09 | 3.13 | 3.04 | 3.09 | 2.82M |
| Oct 13, 2026 | 3.27 | 3.27 | 3.07 | 3.14 | 4.18M |
| Oct 12, 2026 | 3.46 | 3.46 | 3.27 | 3.28 | 2.26M |
| Oct 9, 2026 | 3.49 | 3.53 | 3.43 | 3.46 | 1.66M |
| Oct 8, 2026 | 3.48 | 3.51 | 3.37 | 3.47 | 2.66M |
| Oct 7, 2026 | 3.48 | 3.60 | 3.43 | 3.54 | 3.05M |
| Oct 6, 2026 | 3.78 | 3.82 | 3.48 | 3.52 | 3.45M |
| Oct 5, 2026 | 3.81 | 3.88 | 3.71 | 3.75 | 3.51M |
| Oct 2, 2026 | 3.89 | 3.96 | 3.77 | 3.78 | 3.74M |
| Oct 1, 2026 | 3.95 | 4.07 | 3.78 | 3.88 | 5.41M |
| Sep 30, 2026 | 3.79 | 3.84 | 3.62 | 3.70 | 4.21M |
| Sep 29, 2026 | 3.67 | 3.78 | 3.56 | 3.64 | 2.77M |
| Sep 28, 2026 | 3.77 | 3.78 | 3.60 | 3.67 | 3.55M |
| Sep 25, 2026 | 4.00 | 4.00 | 3.75 | 3.78 | 4.07M |
| Sep 24, 2026 | 3.96 | 4.01 | 3.82 | 3.96 | 3.16M |
| Sep 23, 2026 | 4.27 | 4.35 | 3.92 | 3.95 | 3.97M |
| Sep 22, 2026 | 4.30 | 4.43 | 4.22 | 4.35 | 2.58M |
| Sep 21, 2026 | 4.44 | 4.45 | 4.20 | 4.26 | 2.37M |
About Wave Life Sciences
Wave Life Sciences (WVE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1631574.
WVE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Paul Bolno | President and CEO | Feb 11, 2026 |
| Mark Corrigan | Director | Dec 10, 2025 |
| Christian O Henry | Director | Dec 10, 2025 |
| Peter Kolchinsky | Director | Mar 30, 2026 |
| Capital Management, L.P. Ra | Director | Mar 30, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Mar 30, 2026 |
| Adrian Rawcliffe | Director | Aug 13, 2026 |
| Rajeev M. Shah | Director | Mar 30, 2026 |
| Ken Takanashi | Director | Aug 13, 2026 |
| Aik Na Tan | Director | Aug 13, 2026 |
| Gregory L. Verdine | Director | Dec 10, 2025 |
| Heidi L Wagner | Director | Aug 13, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Paul Bolno | President and CEO | Feb 11, 2026 |
| Chris Francis | See Remarks | Feb 27, 2026 |
| Erik Ingelsson | Chief Scientific Officer | Apr 17, 2026 |
| Kyle Moran | Chief Financial Officer | Feb 11, 2026 |
| Chandra Vargeese | See Remarks | Feb 11, 2026 |
| Christopher I Wright | Chief Medical Officer | Apr 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 12, 2026 | Adrian Rawcliffe | Sale | 12,700 | $5.29 |
| Aug 12, 2026 | Adrian Rawcliffe | Sale | 12,700 | $5.29 |
| Aug 12, 2026 | Adrian Rawcliffe | Sale | 12,700 | $5.29 |
| Aug 12, 2026 | Adrian Rawcliffe | Sale | 12,700 | $5.29 |
| Aug 11, 2026 | Ken Takanashi | Sale | 3,864 | $6.01 |
| Aug 11, 2026 | Ken Takanashi | Sale | 3,864 | $6.01 |
| Aug 11, 2026 | Ken Takanashi | Sale | 3,864 | $6.01 |
| Aug 11, 2026 | Ken Takanashi | Sale | 3,864 | $6.01 |
| Aug 11, 2026 | Heidi L Wagner | Sale | 7,000 | $6.01 |
| Aug 11, 2026 | Heidi L Wagner | Sale | 7,000 | $6.01 |
| Aug 11, 2026 | Heidi L Wagner | Sale | 7,000 | $6.01 |
| Aug 11, 2026 | Heidi L Wagner | Sale | 7,000 | $6.01 |
| Aug 11, 2026 | Aik Na Tan | Sale | 432 | $6.01 |
| Aug 11, 2026 | Aik Na Tan | Sale | 432 | $6.01 |
| Aug 11, 2026 | Aik Na Tan | Sale | 432 | $6.01 |
WVE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $42.73M | $-204.38M | -1.21 | $-187.49M |
| Dec 31, 2024 | $108.30M | $-97.01M | -0.70 | $-151.03M |
| Dec 31, 2023 | $113.31M | $-57.51M | -0.54 | $-19.43M |
| Dec 31, 2022 | $3.65M | $-161.82M | -2.05 | $-127.78M |
| Dec 31, 2021 | $40.96M | $-122.25M | -2.36 | $-88.99M |
Latest balance sheet: total assets $558.32M, total liabilities $104.80M, cash $368.01M (as of Jun 30, 2026).
WVE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $5.76 |
| Apr 28, 2026 | 8-K Item 2.02 (results) | $7.52 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $15.36 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $13.91 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $7.05 |
| Jul 30, 2025 | 8-K Item 2.02 (results) | $8.16 |
| May 8, 2025 | 8-K Item 2.02 (results) | $6.54 |
| Mar 4, 2025 | 8-K Item 2.02 (results) | $11.23 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $15.89 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 6, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on WVE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.